Mizuho Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its price objective lifted by equities researchers at Mizuho from $100.00 to $105.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Mizuho’s price objective points to a potential upside of 19.42% from the company’s previous close.

Several other research analysts have also issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday. Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Finally, Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $87.92 on Wednesday. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $87.22 and a 200-day moving average of $83.93. The firm has a market cap of $50.63 billion, a price-to-earnings ratio of 46.77, a price-to-earnings-growth ratio of 2.19 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,577 shares of company stock worth $3,855,527 over the last 90 days. 0.31% of the stock is owned by company insiders.

Institutional Trading of Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the first quarter valued at $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter valued at $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.